Invasive Fungal Infections

• 

  Subject Areas on Research

  • Breakthrough invasive fungal infections: Who is at risk? 
  • Broad spectrum triazoles for invasive mould infections in adults: Which drug and when? 
  • Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development. 
  • Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. 
  • Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series. 
  • Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry. 
  • Cross-reactivity of a Histoplasma capsulatum antigen enzyme immunoassay in urine specimens from persons with emergomycosis in South Africa. 
  • Emerging Fungal Infections. 
  • Emerging Issues in Antifungal Resistance. 
  • Genomic characterization of recurrent mold infections in thoracic transplant recipients. 
  • Harnessing the Immune Response to Fungal Pathogens for Vaccine Development. 
  • Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. 
  • Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. 
  • Invasive fungal infections in neonates: a review. 
  • Isavuconazole for treatment of rare invasive fungal diseases. 
  • Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. 
  • Let's talk about sex characteristics-As a risk factor for invasive fungal diseases. 
  • Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease. 
  • Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ-Global Registry for Emerging Fungal Infections. 
  • New facets of antifungal therapy. 
  • Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. 
  • Outcomes of cryptococcosis in renal transplant recipients in a less-resourced health care system. 
  • Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population. 
  • Point-of-care diagnostics for invasive aspergillosis: nearing the finish line. 
  • Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. 
  • Reply to Marinelli and Rotstein. 
  • Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. 
  • Risk factors and mortality in invasive Rasamsonia spp. infection: Analysis of cases in the FungiScope® registry and from the literature. 
  • Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections. 
  • The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. 
  • The antifungal pipeline: a reality check. 
  • The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). 
  • Tolerability profile of the current antifungal armoury. 
  • Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019. 
• 

  Keywords of People

  • Schwartz, Ilan, Associate Professor of Medicine, Medicine, Infectious Diseases